Ett utökat åtkomstbehandlingsprotokoll för Zanidatamab (ZW25) hos patienter med HER2-positiv avancerad gallvägscancer
Utökad åtkomst användning av Zanidatamab för behandling av HER2-positiv avancerad solid tumör
This is an intermediate-size Expanded Access Protocol (EAP) for use of zanidatamab (ZW25) in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced biliary tract cancer (BTC) who are not eligible for other zanidatamab clinical trials, and who in the opinion of the treating oncologist, would potentially benefit from treatment with zanidatamab.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Utökad åtkomsttyp
- Befolkning av medelstor storlek
Kontakter och platser
Studieorter
-
-
-
Besançon, Frankrike, 25030
- Jean Minjoz Hospital
-
Marseille, Frankrike, 13385
- Hopital Timone Marseille
-
Pessac, Frankrike, 33604
- Hopital Haut-Leveque - CHU Bordeaux
-
Villejuif, Frankrike, 94805
- Gustave Roussy Cancer Center
-
-
-
-
Arizona
-
Gilbert, Arizona, Förenta staterna, 85234
- NoCo Banner MD Anderson Cancer Center
-
-
California
-
Cerritos, California, Förenta staterna, 90603
- TOI Clinical Research
-
Salinas, California, Förenta staterna, 93901
- Salinas Valley Memorial Healthcare System
-
-
Missouri
-
St Louis, Missouri, Förenta staterna, 63110
- Washington University School of Medicine
-
-
-
-
-
Candiolo, Italien, 10060
- ICCRS Candiolo
-
Milan, Italien, 20133
- Istituto Nazionale Tumori
-
Milan, Italien, 20072
- Istituto Clinico Humanitas
-
-
-
-
-
Barcelona, Spanien, 08035
- Vall D'Hebron University Hospital
-
Madrid, Spanien, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Spanien, 28040
- Fundacion Jimenez Diaz University Hospital - Autonomous University of Madrid
-
-
-
-
-
Harlow, Storbritannien, CM20 1QX
- The Princess Alexandra Hospital NHS Trust (Joanne Kwa, Pharmacist)
-
London, Storbritannien, WC1E 6AG
- UCLH Cancer Institute (Meera Desai, Pharmacist)
-
London, Storbritannien, WC1E 6JA
- HCA Healthcare UK
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Histologically confirmed HER2-positive locally advanced or metastatic biliary tract cancer that has progressed after receipt of available therapies known to confer clinical benefit.
- Adequate cardiac left ventricular function, as defined by left ventricular ejection fraction (LVEF) ≥ 50%
- Adequate organ function
- Ineligible to participate or has no access to an ongoing zanidatamab or other Zymeworks clinical study (e.g., ZW49 clinical study).
- Females of childbearing potential and non-sterile males must agree to practice highly effective methods of birth control for the duration of the study and for 12 months after the last dose of study drug. In addition, non-sterile males must avoid sperm donation for the duration of the study and for 12 months after the last dose of study drug.
Exclusion Criteria:
-
Participating in other studies involving investigational drug(s) ≤ 3 weeks before the first dose of zanidatamab.
-
Systemic anti-cancer therapy ≤ 3 weeks before the first dose of zanidatamab.
-
Radiotherapy ≤ 2 weeks of the first dose of zanidatamab
-
The following central nervous system (CNS) brain lesions are excluded from the study:
-
Untreated or unstable brain lesions requiring immediate local therapy or symptomatic CNS metastases.
-
Radiation treatment for CNS metastases within 4 weeks before the first dose of zanidatamab.
-
Known history of or ongoing leptomeningeal disease (LMD). If LMD has been reported radiographically, but is not suspected clinically by the investigator, the patient must be free of neurological symptoms of LMD.
-
The following CNS brain lesions are permitted:
- Stable brain lesions are permitted if stable, as defined by patients who are off steroids and anticonvulsants and are neurologically stable with no evidence of radiographic progression for at least 4 weeks at the time of screening.
-
-
Concurrent uncontrolled or active hepatobiliary disorders or untreated or ongoing complications after laparoscopic procedures or stent placement, including but not limited to active cholangitis, unresolved biliary obstruction, biloma or abscess. Any complications should be resolved within 2 weeks prior to the first dose of zanidatamab.
-
Active hepatitis
-
Infection with human immunodeficiency virus (HIV) with uncontrolled disease.
-
Females who are breastfeeding or pregnant, and females and males planning a pregnancy.
-
History of myocardial infarction or unstable angina within 6 months prior to enrollment, congestive heart failure (NYHA Class 3 or 4), or clinically significant cardiac disease
-
QTc Fridericia (QTcF) > 470 ms assessed within 30 days of screening
-
Acute or chronic uncontrolled pancreatitis or Child-Pugh Class C liver disease
Studieplan
Hur är studien utformad?
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- ZWI-ZW25-EAP
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .